The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Viral vectors are key delivery tools for advanced therapies, enabling gene transfer to treat inherited disorders, cancer and other serious diseases. Despite rapid clinical progress, manufacturing ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

Dublin, April 20, 2026 (GLOBE NEWSWIRE)-- The "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" report has been added to ...

Switzerland's DINAMIQS receives Swissmedic approval for GMP viral vector production, becoming the country's first fully ...

A recent Views & Comments article published in Engineering highlights advances in repurposing influenza viruses as flexible ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

InVitria, a global leader in chemically defined, animal-origin-free recombinant proteins for advanced therapy manufacturing, announced its participation in the American Society of Gene and Cell ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a ...